Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways

Cancer Biology and Therapy

Volumn 7, Issue 11, 2008, Pages 1818-1828

  Yu, Hong ^a   Gong, Xiaoqi ^a   Luo, Xunyi ^a,b   Han, Wei ^a   Hong, Ge ^a   Singh, Baljit ^a,c   Tang, Careen K ^a,d  

^a GEORGETOWN UNIVERSITY   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d E512 the Research Building ^*  (United States)

Author keywords

Breast carcinoma; Constitutively activated receptor; EGFR; EGFRvIII

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 8; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR VIII;

ANIMAL CELL; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST DUCT; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CARCINOMA CELL; CARCINOMA IN SITU; DOWNSTREAM PROCESSING; EMBRYO; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; MAMMARY GLAND; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STROMA; TUMOR CELL; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CHEMISTRY; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LYMPHATIC METASTASIS; MALE; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 56449102243     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.11.6847     Document Type: Article

References (37)

1. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366:2-16.
2. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A and Schlessinger J. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Nature 1985; 313:144-7.
3. Liu L, Backlund LM, Nilsson BR, Grander D, Ichimura K, Goike HM, Collins VP. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 2005; 83:917-26.
4. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005; 18:1027-33.
5. Ekstrand AJ, Sugawa N, James CD and Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails. Proc Natl Acad Sci USA 1992; 89:4309-13.
6. Yamazaki H, Fukui Y, Ueyama Y, Tamaoki N, Kawamoto T, Taniguchi S and Shibuya M. A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Mol Cell Biol 1988; 8:1816-20.
7. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS and Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992; 89:2965-9.
8. Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer G, Friedman HS, Kwatra MM, Bigner SH, Bigner DD. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Proc Natl Acad Sci USA 1990; 87:207-11.
9. Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, Collins VP, James CD. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 1994; 9:2313-20.
10. Moscatello DK, Holgado-Madruga, Marina, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL and Wong AJ. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Research 1995; 55:5536-9.
11. Okamoto I, Kenyon LC, Emlet DR, Mori T, Sasaki J, Hirosako S, Ichikawa Y, Kishi H, Godwin AK, Yoshioka M, Suga M, Matsumoto M, Wong AJ. Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci 2003; 94:50-6.
12. Garcia de Palazzo I, Adams GP, Sundareshan P, Wong AJ, Testa JR, Bigner DD and Weiner LM. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Research 1993; 53:3217-20.
13. Wikstrand CJ, Hale LP, Batra SK, Hill L, Humphrey PA, Kurpad SK, McLendon RE, Moscatello D, Pegram CN, Reist CJ, Traweek T, Wong AJ, Zalutsky MR and Bigner DD. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995; 55:3140-8.
14. Olapade-Olaopa EO, Moscatello DK, MacKay EH, Horsburgh T, Sandhu DP, Terry TR, Wong AJ, Habib FK. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 2000; 82:186-94.
15. Hong Ge, Xiaoqi Gong and Careen K. Tang. High Incidence of Co-expression of EGFRwt and EGFRvIII Transcripts in Human Invasive Breast Cancer Tissue By Laser Capture Microdissection/RT-PCR. International Journal of Cancer 2002; 98:357-61.
16. Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ, Ritter G, Cohen L, Scanlan MJ, Cavenee WK, Old LJ. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci USA 2003; 100:639-44.
17. Lammering G, Valerie K, Lin PS, Hewit TH, Schmidt-Ullrich RK. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol 2004; 72:267-73.
18. Purev E, Cai D, Miller E, Swoboda R, Mayer T, Klein-Szanto A, Marincola FM, Mick R, Otvos L, Wunner W, Birebent B, Somasundaram R, Wikstrand CJ, Bigner D, DeMichele A, Acs G, Berlin JA, Herlyn D. Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R and de2-7 EGF-R). J Immunol 2004; 173:6472-80.
19. Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 2006; 12:123-30.
20. Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, Marks C, Modjtahedi H. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int J Oncol 2005; 27:317-25.
21. Ou C, Wu FX, Luo Y, Cao J, Zhao YN, Yuan WP, Li Y, Su JJ. Expression and significance of epidermal growth factor receptor variant type III in hepatocellular carcinoma. Ai Zheng 2005; 24:166-9.
22. Olapade-Olaopa EO, Moscatello DK, MacKay EH, Sandhu DP, Terry TR, Wong AJ, Habib FK. Alterations in the expression of androgen receptor, wild type-epidermal growth factor receptor and a mutant epidermal growth factor receptor in human prostate cancer. Afr J Med Med Sci 2004; 33:245-53.
23. Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12:5064-73.
24. Sonnweber B, Dlaska M, Skvortsov S, Dirnhofer S, Schmid T, Hilbe W. High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC). J Clin Pathol 2006; 59:255-9.
25. Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA, Thomas RK, Sasaki H, Horner JW, Eck M, Mitchell A, Sun Y, Al-Hashem R, Bronson RT, Rabindran SK, Discafani CM, Maher E, Shapiro GI, Meyerson M, Wong KK. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 2006; 103:7817-22.
26. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, Traweek T, Wong AJ, Zalutsky MR and Bigner DD. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995; 55:3140-8.
27. James M. Rae, Joshua O. Scheys, Kim M. Clark, Robert B. Chadwick, Michael C. Kiefer and Marc E. Lippman. EGFR and EGFRvIII Expression in Primary Breast Cancer and Cell Lines Breast Cancer Research and Treatment 2004; 87:87-95.
28. Luo X, Gong X, Tang CK. Suppression of EGFRvIII mediated proliferation and tumorigenesis of breast cancer cells by ribozyme. Int J Cancer 2003; 104:716-21.
29. Deepti B. Ramnarain, Seongmi Park, Diana Y. Lee, Kimmo J. Hatanpaa, Shane O. Scoggin, Hasan Otu, Towia A. Libermann, Jack M. Raisanen, Raheela Ashfaq, Eric T. Wong, Julian Wu, Robert Elliott and Amyn A. Habib. Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells Cancer Research 2006; 66:867-74.
30. Mirko H.H. Schmidt, Daniela Hoeller, Jiuhong Yu, Frank B. Furnari, Webster K. Cavenee, Ivan Dikic and Oliver Bögler. Alix/AIP1 Antagonizes Epidermal Growth Factor Receptor Downregulation by the Cbl-SETA/CIN85 Complex Molecular and Cellular Biology 2004; 24:8981-93.
31. Wei Han, Tao Zhang, Hong Yu, John G. Foulke and Careen K. Tang. Hypophosphorylation of Residue Y1045 Leads to Defective Downregulation of EGFRvIII," Cancer Biology & Therapy 2006; 5.
32. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D, 2nd, Thor AD. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005; 23:1152-60.
33. Silva HA, Abraul E, Raimundo D, Dias MF, Marques C, Guerra C, de Oliveira CF, Regateiro FJ. Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients. Eur J Cancer 2006; 42:2617-22.
34. Silva HC, Garcao F, Coutinho EC, De Oliveira CF, Regateiro FJ. Soluble VCAM-1 and E-selectin in breast cancer: relationship with staging and with the detection of circulating cancer cells. Neoplasma 2006; 53:538-43.
35. Normanno N, Maiello MR, De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol 2003; 194:13-9.
36. Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Vigano L, Fumagalli M, Menard S, Gianni L. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. J Cell Physiol 2004; 198:259-68.
37. Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 2000; 60:3081-7.